Serine News and Research

RSS

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Now, an intriguing recent study appeared on the bioRxiv * preprint server describes the use of in vitro evolution to elicit affinity maturation of the viral receptor-binding domain (RBD) of the spike protein to bind the host cell angiotensin-converting enzyme 2 (ACE2) with greater affinity.

7 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

Glycyrrhizin in licorice root neutralizes SARS-CoV-2 in vitro by inhibiting the main protease Mpro

In a recent bioRxiv* preprint paper, researchers from Germany analyzed aqueous licorice root extract for its neutralizing activity against SARS-CoV-2 in vitro. They identified glycyrrhizin, the primary active ingredient in the root, and revealed the underlying mechanism of viral neutralization.

5 Jan 2021

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.

4 Jan 2021

Animal study suggests palmitoylation inhibitor reduces virulence of SARS-CoV-2

A new study preprint on the bioRxiv* server demonstrates the ability of a fatty acid synthase inhibitor to improve the survival of mice infected with murine hepatitis virus. In so doing, it adds to the sum of knowledge about the relationship of SARS-CoV-2 with cholesterol metabolism in the host cell.

24 Dec 2020

COVID-19 severity could be linked to genetic variance

A new study describes some potentially important genetic factors in the host that may shape the clinical symptoms and signs of the disease.

23 Dec 2020

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

COVID-19: Meta-analysis unveils adversely affected biological processes in infected lung cells

The researchers Wasco Wruck and Prof. James Adjaye from the Institute of Stem Cell Research and Regenerative Medicine, Medical Faculty of Heinrich-Heine-University Duesseldorf, Germany, employed a bioinformatic approach on transcriptome data pertaining to human lung epithelial cells infected with SARS-CoV-2.

21 Dec 2020

Remdesivir inhibits SARS-CoV-2 replication by preventing RdRp-mediated RNA translocation

A new study describes the in vitro mechanism by which remdesivir kinetically inhibits the replication of the virus that causes COVID-19, SARS-CoV-2.

18 Dec 2020

Scientists develop an enhanced version of phototoxic protein

Scientists from Skoltech, the Institute of Bioorganic Chemistry of RAS, and the London Institute of Medical Sciences (LMS) have developed an enhanced version of SuperNova, a genetically encoded phototoxic synthesizer, that helps control intracellular processes by light exposure.

17 Dec 2020

Autoimmune condition biomarkers promote SARS-CoV-2 viral entry, study finds

Researchers have reported that the autoimmune PTPN2 risk variant rs1893217 promotes the expression of the SARS-CoV-2 receptor, ACE2, and thus promotes cellular entry, which is mediated by SARS-CoV-2 spike S protein.

16 Dec 2020

RedHill Biopharma announces promising preliminary results from opaganib study

TEL AVIV, Israel and RALEIGH, NC, December 15, 2020, RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced promising preliminary results from a preclinical study with opaganib.

15 Dec 2020

Hybrid approach reveals details about genes involved in Meier-Gorlin syndrome

Meier-Gorlin syndrome, or MGS, is a rare genetic developmental disorder that causes dwarfism, small ears, a small brain, missing patella and other skeletal abnormalities. In severe cases, MGS results in miscarriages and stillbirths.

14 Dec 2020

The effects of cigarette smoke and COPD on SARS-CoV-2 infection

Researchers have revealed some of the effects of cigarette smoke and chronic obstructive pulmonary disease (COPD) on SARS-CoV-2 infection.

9 Dec 2020

Potential SARS-CoV-2 antiviral: Ionophore X-206 found to inhibit viral replication in cell cultures

In a study published in the journal Antiviral Research, researchers from Aarhus University, Denmark, report on their tests on different polyether ionophores to inhibit SARS-CoV-2 in vitro.

1 Dec 2020

Study exposes human olfactory and brain cells as genuine viral targets of SARS-CoV-2

In a study published in the iScience journal, a research group from Switzerland shows that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptors and entry genes are expressed in the human olfactory neuroepithelial cells and brain by observing key molecular players implicated in the infectious process

29 Nov 2020

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

In a recent cutting-edge study, US researchers unveiled an anti-staphylococcal enterotoxin B monoclonal antibody that can be repurposed to target the cleavage site of the SARS-CoV-2 spike glycoprotein and, in turn, inhibit viral infection. Their findings are currently available on bioRxiv preprint server.

25 Nov 2020

Mefloquine shows potential as anti-SARS-CoV-2 drug

A team of scientists from Japan has identified the approved anti-material drug, mefloquine, as a potential candidate to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Specifically, mefloquine has been shown to prevent the entry of SARS-CoV-2 into host cells and reduce the viral load in vitro.

24 Nov 2020

Aprotinin inhibits SARS-CoV-2 entry and replication in cells cultures

Researchers at the University of Kent in the UK and the Hannover Medical School and Goethe University in Germany have observed that the protease inhibitor aprotinin can inhibit viral replication by preventing SARS-CoV-2 entry into host cells.

24 Nov 2020

COVID-19: HLA class I genotypes and mortality

The study, published on the preprint server medRxiv, explores the ability of HLA class I molecules to mediate the outcome in COVID-19 patients.

24 Nov 2020

Serine News and Research

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

Glycyrrhizin in licorice root neutralizes SARS-CoV-2 in vitro by inhibiting the main protease Mpro

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Animal study suggests palmitoylation inhibitor reduces virulence of SARS-CoV-2

COVID-19 severity could be linked to genetic variance

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

COVID-19: Meta-analysis unveils adversely affected biological processes in infected lung cells

Remdesivir inhibits SARS-CoV-2 replication by preventing RdRp-mediated RNA translocation

Scientists develop an enhanced version of phototoxic protein

Autoimmune condition biomarkers promote SARS-CoV-2 viral entry, study finds

RedHill Biopharma announces promising preliminary results from opaganib study

Hybrid approach reveals details about genes involved in Meier-Gorlin syndrome

The effects of cigarette smoke and COPD on SARS-CoV-2 infection

Potential SARS-CoV-2 antiviral: Ionophore X-206 found to inhibit viral replication in cell cultures

Study exposes human olfactory and brain cells as genuine viral targets of SARS-CoV-2

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

Mefloquine shows potential as anti-SARS-CoV-2 drug

Aprotinin inhibits SARS-CoV-2 entry and replication in cells cultures

COVID-19: HLA class I genotypes and mortality

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News